Compare Regeneron Pharmaceuticals Inc (REGN) vs Tilray Brands Inc (TLRY) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

Tilray Brands (TLRY) trades at $3.715, down 1.72% on the day, as the stock continues to face significant pressure with bearish technical signals and fundamental challenges. The company reported a substantial net loss of $2.19 billion in 2025 despite $821 million in revenue, with negative cash flow from operations of $94.6 million. Recent earnings have consistently missed expectations, and technical indicators show a bearish trend with the stock trading near key support levels.

While TLRY shows attractive valuation metrics with P/S of 0.45 and P/B of 0.34, the company faces substantial execution risks amid persistent losses and negative cash flow. Analyst sentiment remains cautious with only 25% buy ratings, though the consensus price target of $65.01 suggests significant upside potential if the company can achieve profitability and growth targets.